What CoolTech does

CoolTech, operating as CoolTech Medical and legally CoolTech LLC, is a Maryland-based medical device company developing non-invasive transnasal cooling technology for targeted patient temperature management. Its sole product, the CoolStat device, delivers filtered, dry, room-temperature air in a unidirectional fashion through a nasal mask; the air flows over the highly vascularized nasal turbinates, where the phase change of liquid to gas extracts heat and induces systemic cooling without cooling pads, refrigeration carts, or external cooling systems. The device features closed-loop temperature control with operator-selectable targets, seamless hospital monitor and EMR integration, and a single-use air tubing consumable that minimizes infection risk.

The intended business model is a capital-equipment-plus-consumables hardware sale into hospitals and healthcare institutions once regulatory clearance is secured, distributed through enterprise field sales. The platform is being investigated across multiple indications: neurogenic (central) fever following stroke, traumatic brain injury, seizure, and metabolic encephalopathy (the lead indication, with the first multi-center clinical study completed in 2022); pre-hospital mild hypothermia induction post sudden cardiac arrest; and migraine pain reduction. The company currently has no commercial revenue and operates in a clinical-research-only distribution mode.

CoolTech employs 11–50 staff and has been supported by approximately $16 million in combined grants and private funding over its history, including a $1,135,000 private round in 2015, an Abell Foundation grant, a $200,000 seed from TEDCO in October 2022, and a $500,000 TEDCO follow-on in September 2025. It maintains a strategic co-development collaboration with Mi-Helper, Inc. on therapies for pain management and mood disorders, signaling intent to extend the technology beyond temperature management. The regulatory pathway (FDA clearance for the investigational CoolStat) remains the critical gating event for transitioning from a clinical-stage development company to a commercial medical device vendor.

Name

CoolTech

Legal name

CoolTech LLC

Website

https://cooltechcorp.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

CoolTech is a Maryland-based medical device company developing the CoolStat transnasal cooling device, which uses evaporative cooling of dry air over nasal turbinates to provide non-invasive targeted temperature management for hospitals.

Ownership category

akta.pro rank

Product category

Targeted Temperature Management Devices

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Continuous Temperature & Fever Monitoring (Wearable Thermometry) (HLAHACAK)

Keywords

• Transnasal cooling devices
• Targeted temperature management
• Medical cooling technology
• Neurogenic fever treatment
• Patient temperature management

Headquarters

HQ city

Toronto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales (Future): Once regulatory clearance is obtained, CoolTech will generate revenue through the sale of the CoolStat device and associated single-use consumables (air tubing sets). The model will likely include capital equipment sales to hospitals with recurring revenue from disposable consumables.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

CoolTech develops the CoolStat device, a portable investigational medical device that delivers filtered, dry, room temperature air through a nasal mask to induce systemic cooling via evaporative phase change at the highly vascularized nasal turbinates. The device features a closed-loop temperature control system that allows clinicians to set and automatically maintain a target patient temperature. CoolStat is currently designated for investigational use only and is being evaluated in clinical studies for neurogenic fever management, pre-hospital mild hypothermia post cardiac arrest, and migraine pain reduction.

Product overview

CoolTech is a medical device company with a single core product offering: the CoolStat device. CoolStat is a portable targeted temperature management system that uses a novel transnasal evaporative cooling approach to cool patients. Unlike traditional cooling methods using pads or refrigeration carts, CoolStat delivers dry room temperature air through a nasal mask, leveraging the highly vascularized nasal turbinates to induce systemic cooling. The device includes a closed-loop temperature control system and is designed for use in clinical settings for neurogenic fever management, post-cardiac arrest hypothermia initiation, and migraine pain reduction. The company is currently conducting clinical studies as the device has not yet been cleared or approved for commercial use.

Differentiator

Problem solved

Functional benefit

Brands

• CoolStat: A medical device for patient temperature management using evaporative cooling via transnasal dry air delivery. The device is designed for targeted temperature management (TTM) and is currently designated for investigational use only.

Products and services

• CoolStat CoolStat is a portable investigational medical device that delivers filtered, dry, room temperature air through a nasal mask to induce systemic cooling via evaporative phase change at the nasal turbinates. It includes a closed-loop temperature control system that allows clinicians to set and automatically maintain a target patient temperature. The device is currently designated for investigational use only and is being evaluated in clinical studies for neurogenic fever management, pre-hospital mild hypothermia induction post sudden cardiac arrest, and migraine pain reduction.

Quantifiable outcome

• Completed first multi-center clinical study in 2022 for neurogenic fever indication
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

One partnership is on record.

• Mi-Helper, Inc.minorStrategic or Co-development PartnerMi-Helper, Inc. collaborates with distinguished scientists and clinicians at CoolTech on a mission to develop cutting-edge therapies for unmet needs in pain management and mood disorders. This collaboration supports the company's broader therapeutic applications beyond temperature management.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BrainCool AB: BrainCool markets RhinoChill, a transnasal cooling device for therapeutic hypothermia and fever management — the closest direct mechanism-level competitor to CoolTech's CoolStat, sharing both target indications and core evaporative/cooling technology.
• EMCOOLS: EMCOOLS produces flexible surface cooling pads (Emcoolspad) and an intracranial cooling catheter (Cool Flow) for targeted temperature management, making it a direct competitor in TTM and fever control across overlapping clinical indications.

Broad incumbents

• Becton Dickinson (BD): BD owns the Arctic Sun targeted temperature management system, the dominant surface-cooling platform in hospitals worldwide. It competes with CoolStat across neurogenic fever, cardiac arrest, and ICU temperature management as the entrenched TTM category leader.
• ZOLL Medical (Asahi Kasei): ZOLL markets the Thermogard XP intravascular TTM platform widely used in post-cardiac arrest care and ICU normothermia. It is a broad incumbent in exactly the indications (cardiac arrest, fever management) CoolTech is pursuing.
• Stryker: Stryker's Altrix connects to multiple patient warming/cooling modalities across perioperative and critical care settings, providing an enterprise-scale TTM alternative that hospitals may prefer for installed-base and bundling reasons over a novel transnasal device.

Emerging players

• Attune Medical: Attune Medical's ensoETM is an esophageal cooling device for targeted temperature management in the ICU and cardiac arrest settings, positioning it as a differentiated emerging modality adjacent to CoolStat's transnasal approach.
• Belmont Medical Technologies: Belmont Medical (a successor to Medivance-related assets) supplies high-flow fluid warming and rapid infusion devices used alongside TTM workflows in trauma and critical care, making it a comparable platform in the broader temperature/critical care space.

Others

• Vyaire Medical: Vyaire Medical supplies respiratory care and ventilation products to hospitals, an ecosystem adjacency to CoolTech's nasal-interface cooling approach and a potential distribution/sales counterpart for hospital-channel go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoolTech